

GLOBAL TRENDS OF PHARAMCEUTICAL INDUSTRY (LUPIN Ltd)

**-KIMAYA YOGESH SAVE
IIHMR-U/02/2022-24/0395**

Table of contents

Introduction

Product sales mix

Product sales

Therapy ranking

Complication

Strategies

Opportunities

Analysis and recommendation

INTRODUCTION

The pharmaceutical market is projected for growth at a compound annual growth rate (CAGR) of 4.5%, between an estimated value of \$1.3 trillion in 2022 to a valuation of \$1.9 trillion in 2027, in accordance to the 2023 January publication of IQVIA Market Forecast. Global drug expenditures are expected to exceed pre-pandemic forecasts in 2020 and 2027, mainly due to greater spending on COVID-19 vaccines and treatments, as well as impacts on various healthcare domains. Drug use globally peaked in 2022 after a notable rebound in 2021 as the market emerged from the pandemic

- 
- 6th Rank In Indian Pharma Market
 - Lupin now has Eight brands in the Top 300 brands category of the IPM

1. Gluconorm-G

2. Ajaduo

3. Budamate


4. Tonact

5. Huminsulin

6. Ondero

7. Ivabrad


8. Rablet-D




LUPIN



INDIAN PHARMACEUTICAL MARKET



(Salience%)




Source: IQVIA MAT March 2023 (MIDAS)

PRODUCT SALES MIX


FY 2019 PRODUCT SALES MIX

North America India APAC EMEA LATAM ROW API NCE




FY 2023 PRODUCT SALES MIX

India North America EMEA ROW API Growth market



Therapy wise ranking



COMPLICATIONS

- Failure to Stabilize Price Trajectories
- Geopolitical Fragmentation
- Competitive Risk and Pricing Pressure
- Inability to Maintain Steady Price Trends
- There's been pressure on prices, particularly in the US. How is Lupin addressing the current scenario?
- How are you managing with the US FDA's constantly shifting regulations?
- What has been the company's achievement in the branded generics region, especially in India and emerging markets?

STRATEGIES

Strengthen leadership in market

Expand basket of complex generics in U.S and other markets

Continue to prioritize regulatory compliance

Excellence in execution

Building a sustainable future

OPPORUTINITES



Strategic expansion into the specialty drugs market



Leveraging technological advancements for efficient R&D



Increasing market share in key emerging markets



Exploring strategic partnerships and acquisitions for growth



Analysis and Recommendations



THANK YOU

